A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The primary objective of the study is to compare PFS of subjects treated with BMN 673 asa monotherapy relative to those treated with protocol-specific physician?s choice.
Description
The primary objective of the study is to compare PFS of subjects treated with BMN 673 asa monotherapy relative to those treated with protocol-specific physician?s choice.
Details
| Condition | breast cancer |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX7263 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.